Skip to content

Climb Bio, Inc. CLYM Change in Other Liabilities

Change in Other Liabilities at other companies

Amgen logo
AmgenAMGN
-$75M+3.8%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-$1.36M-125%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Climb Bio, Inc.’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s change in other liabilities?
Climb Bio, Inc. (CLYM) reported change in other liabilities of $0 in Q4 2025.
How has Climb Bio, Inc.'s change in other liabilities changed year-over-year?
Climb Bio, Inc.'s change in other liabilities increased by 100.0% year-over-year, from -$5.5K to $0.
What does change in other liabilities mean?
Change in miscellaneous liabilities affecting operating cash flow.